NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is i

SHAREHOLDER ALERT: Purcell and Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeut

NEW YORK, July 16, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating K

Mizuho analyst Joseph Catanzaro maintains Kymera Therapeutics (NASDAQ:KYMR) with a Outperform and

RBC Capital analyst Brian Abrahams downgrades Kymera Therapeutics (NASDAQ:KYMR) from Outperform t

B of A Securities analyst Tazeen Ahmad maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and

Truist Securities analyst Srikripa Devarakonda maintains Kymera Therapeutics (NASDAQ:KYMR) with a

B. Riley Securities analyst Kalpit Patel maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy a

Canaccord Genuity analyst Edward Nash maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and

Kymera Therapeutics shares surged after completing KT-621 Phase 2b enrollment early, accelerating da

BTIG analyst Jeet Mukherjee reiterates Kymera Therapeutics (NASDAQ:KYMR) with a Buy and maintain

U.S. stocks traded mostly higher, with the Nasdaq Composite down 0.1%. Industrials jumped 2.5%, whil

Dow Jones index gained 200 points; Acuity Inc (NYSE: AYI) reported better-than-expected financial re

BROADEN2 enrollment completed nearly six months ahead of anticipated timelinesKT-621 Phase 3 trials

Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new

U.S. stocks up with Dow Jones gaining 200+ points. AbbVie Inc. announced acquisition of Apogee Thera

"The consistency we've demonstrated across KT-621 Phase 1 studies, from robust STAT6 degrada

First-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million miles

KT-579 demonstrated consistent disease-modifying activity comparable or superior to approved and cli

Society for Investigative Dermatology (SID) 2026 Annual MeetingTitle: KT-621 Treatment Induces Rapid

Canaccord Genuity analyst Edward Nash initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) wit

The Company previously reported data demonstrating KT-579's compelling profile in preclinical st

Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.71) per share which beat the anal

KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027KT-621 B

Gilead expands Tempus AI deal and licenses Kymera's KT-200, advancing oncology pipeline with dat

KT-200 is a first-in-class, oral CDK2 molecular glue degrader development candidate Option exercise

US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen

Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supportin

Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new

UBS analyst David Dai maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price

Citigroup analyst Geoff Meacham maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises

Stephens & Co. analyst Sudan Loganathan maintains Kymera Therapeutics (NASDAQ:KYMR) with a Ov

  On Monday, 369 companies set new 52-week lows.

  During Thursday's session, 406 companies made new 52-week lows.

  During the session on Thursday, 461 stocks hit new 52-week lows.

  On Wednesday, 216 stocks hit new 52-week lows.

  During Thursday, 849 stocks hit new 52-week lows.